Loading…
Our read is that lowering Alzheimer's risk involves a comprehensive, preventative approach focusing on metabolic health, stress reduction, and sleep optimization.
Our read is that preventative measures for dementia should be taken by all individuals with a brain, not just those at high risk, as suggested by Peter Attia. A systems-level strategy is recommended, encompassing a healthy vascular supply, available metabolic substrate for neurons, necessary nutrients, absence of impairing factors, demand on the system to drive adaptation, and periods of recovery and adaptation, according to Peter Attia.
Our read is that improving strength, endurance, stamina, balance, coordination, processing speed, working memory, emotional health, happiness, and relationships may provide approximately 75% of the benefits towards optimizing lifespan, as noted by Peter Attia.
Our read is that a ketogenic diet, high in saturated fats and low in carbohydrates, improved a heterozygous APOE4 male with type 2 diabetes's Montreal Cognitive Assessment score, reversed his type 2 diabetes, improved markers of metabolic syndrome, and led to weight loss, as observed by Rhonda Patrick and Paul Saladino. Paul Saladino also suggests that individuals with insulin sensitivity can consume saturated fats from animal foods, even with APOE4, as these may protect against dementia. Peter Attia notes that Alzheimer's research is investigating if ketogenic interventions can reduce amyloid plaque accumulation over 2-10 years, measured by PET scans. Paul Saladino adds that ketones, specifically beta-hydroxybutyrate, can suppress the NLRP3 inflammasome. Andrew Huberman suggests that ketogenic diets may be used to treat schizophrenia. Our read is that chronic stress can cause hippocampal shrinkage and worsen Alzheimer's predisposition, schizophrenia, and addiction relapse, according to Andrew Huberman. Rhonda Patrick and Peter Attia indicate that selective deprivation of deep non-REM sleep or sleep fragmentation leads to immediate amyloid buildup in the brain in animal studies. David Sinclair notes that SIRT3 activation protects against oxidative stress, mitochondrial dysfunction, metabolic disorders, DNA damage, senescence, cell death, heart disease, neurodegenerative diseases, inflammation, skin and bone aging, and hearing loss.
Our read is that targeting amyloid alone may not be sufficient or may be too late for treating cognitive decline, as Rhonda Patrick suggests. Paul Saladino notes that an Alzheimer's drug that changes beta-amyloid in the brain has been approved by the FDA despite an advisory committee voting against approval due to potential harm. Paul Saladino also states that individuals with APOE4 do not need to avoid saturated fat due to a lack of mechanistic basis for saturated fat worsening Alzheimer's disease. Peter Attia indicates that trans fats in the blood are associated with increased Alzheimer's risk. Andrew Huberman warns that starting cannabis use as young as age 12 or 14 more than doubles the probability of later-life psychosis. Rhonda Patrick suggests that pharmaceutically-induced sleep may be associated with cancer and changes in neural plasticity. Peter Attia notes that the 'leaky gut' hypothesis lacks evidence as a cause for autism spectrum disorder. Paul Saladino claims that the assertion that high animal protein diets accelerate aging is based solely on studies of triple transgenic mice models of Alzheimer's disease. Paul Saladino also suggests that aquaporins found in foods like corn, soybeans, spinach, and tomatoes may share homology with human aquaporin-4 and could potentially cause neurological tissue damage. Peter Attia states that a whole genome sequence or 23andme analysis rarely alters treatment plans beyond existing clinical knowledge, with few exceptions like identifying a Tom 40 mutation increasing Alzheimer's risk. Paul Saladino notes that methylene blue can increase the amount of falls in Alzheimer's patients with compromised mitochondrial electron transport chains.
Our read is that the understanding of Alzheimer's disease could change if the role of amyloid plaques is fully understood, as Andrew Huberman suggests that healthy individuals can have significant amyloid buildup without cognitive impairment. Peter Attia notes that the amyloid-beta hypothesis for Alzheimer's disease may be incorrect, and that amyloid beta may not be necessary or sufficient to cause dementing processes. Peter Attia also states that it is unknown whether the accumulation of hexane or other industrial solvents from seed oils could contribute to chronic health processes like neurodegenerative diseases, cancer, or cardiovascular disease. David Sinclair suggests that bacteria that cause gum disease may contribute to Alzheimer's disease, but this is uncertain. Peter Attia also notes that the scientific understanding of CTE and its relationship to accumulated sub-concussive injuries is still evolving. David Sinclair indicates that the efficacy of humanin and MOTS-C in humans for treating neurodegenerative diseases like Alzheimer's is not yet clear. Peter Attia also notes that the utility of the C2N test in assessing risk and tracking intervention effectiveness is still in early stages.
Carriers of two copies of APOE4 have a 12-fold increased chance of developing Alzheimer's disease, while carriers of one copy have a two to four-fold increased chance.
The intervention improves the primary outcome at standard doses in healthy adults.
Amyloid beta plaques can interfere with neuronal synapses and inhibit deep sleep, creating a vicious cycle with poor sleep.
The intervention improves the primary outcome at standard doses in healthy adults.
The intervention improves the primary outcome at standard doses in healthy adults.
Animal-model results don't translate to the human protocol being recommended.
The headline effect shrinks once you account for trial quality.
Most of the support comes from short or small studies.
Confounding and publication bias inflate the apparent benefit.
Most of the support comes from short or small studies.